Furthermore, overexpression of ILK and Src homology 2 (SH2) domain–containing phosphatase 2 (SHP2) is associated with poor outcomes in patients with epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) who receive monotherapy with EFGR tyrosine kinase inhibitors (TKIs), suggesting both a potential avenue for stratification of patients with EGFR mutations and a rationale for combinatorial approaches using EGFR TKIs and targeted inhibitors of ILK and SHP2 [72]. This evidence concerns the gene ILK and non-small cell lung carcinoma.